Title:
ENGINEERED CELLS FOR THERAPY
Document Type and Number:
WIPO Patent Application WO/2022/235811
Kind Code:
A3
Abstract:
Strategies, systems, compositions, and methods for genetically modifying cells to include one or more loss-of-function modifications and/or to include one or more gain-of-function modifications, as well as modified cells (and compositions of such cells) that include one or more loss-of-function modifications and/or that include one or more gain-of-function modifications, are described. In certain aspects, such modified cells include at least one gain-of-function modification within a coding region of an essential gene.
Inventors:
ZURIS JOHN ANTHONY (US)
MARGULIES CARRIE MARIE (US)
MARGULIES CARRIE MARIE (US)
Application Number:
PCT/US2022/027685
Publication Date:
December 15, 2022
Filing Date:
May 04, 2022
Export Citation:
Assignee:
EDITAS MEDICINE INC (US)
International Classes:
A61K38/20; C12N15/09
Domestic Patent References:
| WO2020168300A1 | 2020-08-20 |
Foreign References:
| US8980940B2 | 2015-03-17 | |||
| US20200283778A1 | 2020-09-10 |
Other References:
IMAMURA, M ET AL.: "Autonomous growth and increased cytotoxicity of natural killer cells expressing membrane-bound interleukin-15", BLOOD, vol. 124, no. 7, 8 July 2014 (2014-07-08), pages 1081 - 1088, XP055237400, DOI: 10.1182/blood-2014-02-556837
Attorney, Agent or Firm:
GONCHAROFF, Dustin K. et al. (US)
Download PDF:
Previous Patent: A BIOLOGICAL ENTITY FOR TREATING BRAIN CANCER
Next Patent: THERMAL INTERFACE MATERIALS WITH RUBBER COMPATIBILITY
Next Patent: THERMAL INTERFACE MATERIALS WITH RUBBER COMPATIBILITY